WVE Wave Life Sciences Ltd.

+0.77  (+3%)
Previous Close 26.23
Open 26.14
Price To Book 4.7
Market Cap 925,144,227
Shares 34,264,601
Volume 138,953
Short Ratio
Av. Daily Volume 282,722

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2a top line data due by YE 2019.
Huntington’s disease
Phase 1b/2a top line data due by YE 2019.
Huntington’s disease
Phase 1 interim efficacy data from open-label trial due 2H 2019. Phase 2/3 trial initiation announced June 27, 2019.
Suvodirsen (WVE-210201)
Duchenne muscular dystrophy - Exon 51

Latest News

  1. Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues
  2. Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
  3. Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
  4. Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference
  5. Vertex enters Duchenne field with $245M buy of Exonics
  6. Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates
  7. Wave Life Sciences: 1Q Earnings Snapshot
  8. Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
  9. Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?
  10. Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  11. What Are Analysts Saying About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Earnings Trajectory?
  12. Wave Life Sciences Plunges After DMD Study Data Readout
  13. The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
  14. Qualcomm and Progressive jump while Wave Life Sciences drops
  15. Why Wave Life Sciences's Valuation Is Falling By 25%
  16. Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
  17. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  18. Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
  19. Wave Life Sciences Plunges on Clinical Trial Data Delay
  20. Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs